- A primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text
Revision diagnosis of panic disorder with or without agoraphobia based on the
Mini-International Neuropsychiatric Interview for Children and Adolescents
- Subjects with an average of 1) at least one 4-symptom panic attack per week over the
last 4 weeks before screening; 2) at least one 4-symptom panic attack per week over
the last 4 weeks before baseline; and 3) at least one 4-symptom panic attack in the 7
days prior to baseline
- To enter Study A6131007, subjects must have completed Study A6131002, had an
acceptable tolerability to study drug, and in the clinical judgment of the
investigator, could have benefited from continued study treatment.
- Subjects must continue to meet all of the exclusion criteria enumerated in the Acute
Efficacy Study (Protocol A6131002) with the following exception: Subjects will be
allowed to undergo cognitive-behavioral or other panic-specific therapy and any other
psychotherapy (e.g., supportive and/or family therapy) during the expected study
period in this study.